Calysta's Groundbreaking Approach to Food and Feed Production

Calysta is revolutionizing the way we produce food and feed, using a unique approach that's changing the game.

Their innovative technology utilizes a single-cell protein source, called Allia, which is produced through a fermentation process.

This method is more sustainable and environmentally friendly compared to traditional feed production methods.

By using Allia, Calysta aims to reduce the environmental impact of livestock production, while also increasing the efficiency of feed production.

Calysta's technology has the potential to improve the lives of millions of people worldwide, by providing a more sustainable source of food and feed.

If this caught your attention, see: Is Forbes a Reliable Source

Calysta, a leading alternative protein producer, has received a significant boost with a $39 million investment for FeedKind production. This funding round was led by bp ventures and will support the global scale-up of production of Calysta's FeedKind protein.

The expansion of the Series D-1 funding round will enable Calysta to scope and pre-develop its next manufacturing site outside of Asia. Calysta is currently working on completing the world's first commercial FeedKind production facility in China via Calysseo, its 50/50 joint venture with Adisseo.

Thomas Huot, Calysta's COO, explained that the expansion of FeedKind production beyond Asia will help convert low-cost natural gas resources into high-value, environmentally friendly protein alternatives. This is crucial in addressing the challenges faced by global food and protein supply chains.

Calysta's technology produces sustainable single-cell protein through a proprietary, commercially validated gas fermentation process using naturally occurring, non-GM microbes that use methane as their energy source. This process makes more from less, utilizing abundant natural gas resources to produce feed for fish, livestock, and pets.

The investment will also enable Calysta to work closely with its strategic partners at bp and Adisseo as it expands its FeedKind production globally. Calysta will benefit from bp's operational excellence and focus on delivering sustainable energy, while Adisseo will accelerate commercialization of the product and support sales and marketing efforts in Asia.

Meghan Sharp, head of bp ventures, stated that Calysta's innovation offers an opportunity to deliver sustainable protein for the planet and supports bp's strategy of creating new markets in which gas can play a material role in delivering a more sustainable future.

Consider reading: Sustainable Investing Trends

Calysta has been approved by China's Ministry of Agriculture and Rural Affairs to use its FeedKind protein in fish and shrimp feeds.

Calysta's FeedKind protein is a nutritionally rich and non-GMO protein ingredient that helps preserve biodiversity while addressing a growing market need for proteins for feed and food.

The FDA has granted Calysta's FeedKind protein GRAS status for use in the US in salmonid feeds at up to 18% of the diet.

Calysta's FeedKind protein can be produced year-round using no arable land and without using any plant or animal ingredients, making it a protein without limits.

Calysta has successfully switched on its first commercial-scale facility via Calysseo, its joint venture with animal feed giant, Adisseo, providing 20,000 tons of protein for the Asian aquaculture market.

Calysta's FeedKind protein has a far lower carbon footprint than conventional sources of animal protein and can help pet food and animal feed producers achieve their carbon reduction targets.

Calysta's FeedKind protein is free from heavy metals, pesticides, and microplastics, ensuring animals are only fed the nutrients they need.

Calysta is expanding its production footprint in the Kingdom of Saudi Arabia through its joint venture Calysseo.

Readers also liked: Using Cash vs Card Psychology

Calysta's achievements have caught the attention of investors, who can now visit the company's China plant and see the data for themselves, making it easier for them to get behind the project.

The company has received significant funding, including a £2.8 million grant from the UK government in 2016 and $30 million from Cargill the same year.

Calysta's hard work has paid off, with the opening of its first commercial-scale facility in Chongqing, China, which can produce 20,000 tonnes of product per year.

Investors are taking a more favorable view of Calysta's operations due to the company's ability to demonstrate the performance of its China plant.

Calysta's China plant has two fermenters, each with a capacity of 10,000 tons a year, which provides a tangible example of the company's capabilities.

This tangible proof is making it easier for future investors to get behind Calysta, as they can visit the site, see the data, and witness the product firsthand.

Investors can now rely on concrete evidence to inform their investment decisions, rather than just relying on theoretical projections.

Calysta marked a significant milestone in 2016 with the opening of a pilot facility in Teeside, England, thanks to a £2.8 million grant from the UK government.

This was a crucial step in the company's journey, allowing them to perfect their technology over the next decade. Calysta raised $30 million from Cargill in the same year, followed by a further $40 million from investors including Temasek in 2017.

The company's hard work paid off, and they successfully switched on the world's first industrial-scale alternative protein fermenter in Chongqing, China. This facility has the capacity to produce 20,000 tonnes of product per year.

Calysta's co-founder and CEO, Alan Shaw Ph.D., described the moment as "an incredibly proud moment". He highlighted the significance of this achievement, stating that it's a huge step towards making the world more food secure.

Here's an interesting read: Minsky Moment